

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

Transfusion and Apheresis Science



journal homepage: www.elsevier.com/locate/transci

The association of ABO blood group with the asymptomatic COVID-19 cases in India

Prajjval Pratap Singh^{a,*,1}, Abhishek K. Srivastava^{b,1}, Sudhir K. Upadhyay^{c,1}, Ashish Singh^{d,1}, Shashank Upadhyay^e, Pradeep Kumar^f, Vandana Rai^f, Pankaj Shrivastava^g, Gyaneshwer Chaubey^{a,*}, Serosurveillance Consortium BHU²

^a Cytogenetics Laboratory Department of Zoology, Banaras Hindu University, India

^c Department of Environmental Science, Veer Bahadur Singh Purvanchal University, Jaunpur, India

^d Genome Foundation Rural Centre Kalavari, Jaunpur, India

^e Invertis University, Bareilly, Uttar Pradesh, India

^f Department of Biotechnology, Veer Bahadur Singh Purvanchal University, Jaunpur, India

^g DNA Fingerprinting Unit, State Forensic Science Laboratory, Department of Home (Police), Government of MP, Sagar, India

ARTICLE INFO

Keywords: India Blood group Asymptomatic COVID-19 Coronavirus

ABSTRACT

The COVID-19 pandemic resulted in multiple waves of infection worldwide. The large variations in case fatality rate among different geographical regions suggest that the human susceptibility against this virus varies substantially. Several studies from different parts of the world showed a significant association of ABO blood group and COVID-19 susceptibility. It was demonstrated that individuals with blood group O are at the lower risk of coronavirus infection. To establish the association of ABO blood group in SARS-CoV-2 susceptibility, we for the first time analysed SARS-CoV-2 neutralising antibodies among 509 individuals, collected from three major districts of Eastern Uttar Pradesh region of India. Interestingly, we found neutralising antibodies in a significantly higher percentage of people with blood group AB (0.36) followed by B (0.31), A (0.22) and lowest in people with blood group O (0.11). We further estimated that people with blood group AB are at comparatively higher risk of infection than other blood groups. Thus, among the asymptomatic SARS-CoV-2 recovered people blood group AB has highest, whilst individuals with blood group O has lowest risk of infection.

1. Introduction

COVID-19 has impacted life of billions because of its virulence. The extensive ongoing research revealed the complex nature of this novel SARS-CoV-2 virus transmitted to the humans [1–6]. With the growing knowledge about this disease, it is clear that there are certain risk factors associated with morbidity and mortality [7–9]. More importantly, many of the studies have found strong association of the ABO blood group and COVID-19 with morbidity and mortality [6,10–14], whilst, a few studies have also found no association of COVID-19 with the ABO blood group 10,15,16]. In the past, there have been several studies suggesting the association of ABO blood group with diseases. For example, individual with the blood group O were reported to be more susceptible to the

Cholera in Gangetic plain populations [17] and *Helicobacter pylori* infection [18]. However, blood group O was found to be less susceptible for Dengue [19,20] and SARS (Severe Acute Respiratory Syndrome) viruses [14,21].

The ABO blood type is administered by the gene *ABO*, located at chromosome 9 [22]. Studies have found that the this gene modulates the COVID-19 susceptibility directly or indirectly [23–25]. Several genetic variants of this gene affect morbidity and mortality in COVID-19 and many other diseases. For example, it affects red blood related physiology [26,27], venous thromboembolism [28], type 2 diabetes [29], ischemic stroke [30], heart related functions [31] and coronary artery disease [31–33]. Thus, studying the association of ABO blood type with SARS-CoV-2 infection, it is feasible to ascertain the factors influencing

* Corresponding authors.

https://doi.org/10.1016/j.transci.2021.103224

Received 29 May 2021; Received in revised form 22 July 2021; Accepted 27 July 2021 Available online 30 July 2021 1473-0502/© 2021 Elsevier Ltd. All rights reserved.

^b Mohd. Hasan P. G. College, Jaunpur, India

E-mail addresses: prajjvalp.singh3@bhu.ac.in (P.P. Singh), gyaneshwer.chaubey@bhu.ac.in (G. Chaubey).

¹ Equal first author contribution.

 $^{^2}$ The full author details of Serosurveillance Consortium BHU has been given in Supplementary text.




Fig. 1. The comparative bar-plot of various ABO blood groups among studied groups. The error bars have been calculated at 95 % confidence interval.

Table 1
Various statistical tests on our data to infer the association and risk of ABO blood
group for COVID-19. $OR = Odds$ Ratio, $CI = Confidence$ interval.

	А	В	AB	0
Chi square	0.632	2.564	101.331	53.276
p value	0.427	0.109	< 0.001	< 0.001
OR	1.222	0.725	26.783	0.176
95 % CI	0.792 - 1.884	0.500 - 1.052	11.3888 - 62.986	0.108 - 0.288

the susceptibility against SARS-CoV-2 in humans.

In the present study, we sought to investigate the association between asymptomatic COVID-19 positive people with their blood types using random serosurveillance and blood group testing of street vendors in Northern India [34,35].

Materials and Method

In our survey, we used two commercially available kits Coviscreen[™]and ERYCARD[™]2.0 to determine the seropositivity and the blood groups respectively. These kits were contributed by Biosense Technologies, India for research purposes. Similar to our previous work [34], we focussed on the urban populations in our survey. A total of 509 individuals were screened for both the tests. The participants were between the age of 18–65 years from the three districts of the Eastern Uttar Pradesh state (Supplementary Fig. 1). We focussed on the urban healthy vendors who have neither been diagnosed with COVID-19, nor had been sick with any associated symptoms in the recent past. We excluded those individuals whose family members had ever been diagnosed with COVID-19. This study was conducted between months of September 2020 to October 2020. The aim of the study was explained to the people and informed consent were obtained. This study was approved by the ethical committee of Banaras Hindu University, Varanasi, India.

Both COVID-19 and blood group testing was done using manufacturer's instructions provided in the kit. A sample test of CoviscreenTMand ERYCARDTM2.0 is shown in Supplementary Fig. 2. The frequency of seropositive and blood groups was calculated (Supplementary Table 1). The frequency bar plot of each blood group was drawn with 95 % CI (Fig. 1). We have also collected blood group data of the same region for comparison from published sources [36–43].

The data was analysed using two tailed Chi square test. Odds ratio (OR) and 95 % confidence interval (CI) was calculated (Table 1and Supplementary Table 2). Statistical analyses were performed using SPSS (ver. 25).

2. Results and discussion

We collected data of seroprevalence as well as blood group affiliation among 509 individuals from three districts of Eastern Uttar Pradesh region (Supplementary Table 1). The seroprevalence frequency among all the studied districts was >0.4. The high level of seroprevalence among these districts suggests a hidden undercurrent wave of infection mainly driven by asymptomatic individuals. It is imperative to stress that, this is not the story of a particular region of India. Remarkably, other independent regions in the country have also demonstrated a high level of seroprevalence [44,45].Nevertheless, it is not uniform, rather sporadic.

In the collection of random 509 samples, we found a frequency distribution of 0.204, 0.354, 0.279 and 0.163 for blood groups A, B, O and AB respectively (Supplementary Table 1). Blood group B is most common blood group followed by blood group O, whereas blood group AB is least common among the populations of Eastern Uttar Pradesh region. To test if our sampling had covered the representative blood group distribution of this region, we referred to the published data of the same region [36–43] and performed a regression analysis. The adjusted R square value (83.6 % <u>+3</u>.4 %) demonstrated significantly high level of correlation between our data as well as published data, suggesting that our sampling indeed represented the regional distribution of the blood groups.

We further grouped COVID-19 positive samples and estimated their ABO blood group division. The 215 seropositive individuals showed their ABO blood group distribution of 0.223, 0.312, 0.107 and 0.358 for A, B, O and AB blood groups respectively (Supplementary Table 1). The relative comparison of blood group distribution have shown large discrepancy for the blood groups O and AB (Fig. 1). Blood group AB was significantly over-represented, whereas blood group O was significantly under-represented in the seropositive group (p < 0.001) (Table 1). This result was also consistent with the published data (Supplementary Fig. 3 and Supplementary Table 1). Thus, suggested strong association of blood groups O and AB with COVID-19 susceptibility. The risk estimation revealed several fold higher risk of infection to blood group AB and lower risk for blood group O (Table 1 and Supplementary Table 2). At the risk scale, our investigation suggested blood group AB at the maximum, followed by blood group A and B, whereas blood group O had lowest.

We would like to stress that our data do not include COVID-19 severe patients, due to our sampling methodology. Thus, it limit us to understand the association of blood group with the COVID-19 severity. On the other hand, it is highly enriched for the asymptomatic patients. Therefore, our result can also infer an important insight that, though blood group AB has the highest risk of infection, it may not have elevated risk of severity. The large number of hospital data will be able to testify it further.

It has been shown recently that the Rh negative blood type has a protective role against SARS-CoV-2 [12]. We have tested this association and found out 0.333(95 % CI 0.152–0.587) seroprevalence for Rh negative individuals, which is not significantly different than 0.425(95 % CI 0.382–0.469) seroprevalence of Rh positive people (p > 0.05) (Supplementary Table 2). Hence, we did not find any association of Rh factor with COVID-19. However, the limited sample size (n = 15) of Rh negative individuals should be interpreted with caution.

In summary, this is the first study in our knowledge which has been done on association of ABO locus with the COVID-19 susceptibility in India using asymptomatic COVID-19 recovered individuals. Consistent with the previous observations, we have also found that the blood group O has least risk. However, we did not find any higher risk for blood group A as reported earlier, rather we saw severalfold increased risk of infection for blood group AB. With our novel sampling methodology, we focused on asymptomatic COVID-19 individuals. This helped us to deduce that though blood group AB is most susceptible for SARS-CoV-2 infection, nevertheless it is unlikly for them to develop disease severity.

Author contributions

GC and PPS conceived and designed this study. PPS, AKS, SKU, AS, SU, PK, VR, PS and Serosurveillance consortium BHU have collected the field data and performed the antibody as well as blood group testing. PPS and GC analysed the data. PPS, AKS, SKU, AS, CBM and GC wrote the manuscript from the inputs of all the co-authors. All authors contributed to the article and approved the submitted version.

Data availability statement

All datasets generated for this study are included in the article/ Supplementary Material.

Declaration of Competing Interest

The authors declare no competing interests.

Acknowledgements

We are grateful to the Biosense Technologies, India for their kind help in the seroprevalence project. GC and RaKM are supported by Faculty IOE grant BHU (6031), RT and GC are supported by SERB India (CRG/2018/001727), PPS and VS are supported by CSIR fellowship, CBM is supported by Wellcome Trust/DBT India Alliance Early Career Fellowship (IA/E/18/1/504338), RKM is supported by Mahamana Post-Doctoral Fellowship BHU.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.transci.2021.103224.

References

- Aleta A, et al. Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19. Nat Hum Behav 2020;4:964–71.
- [2] Alberca RW, Oliveira L, de M, Branco ACCC, Pereira NZ, Sato MN. Obesity as a risk factor for COVID-19: an overview. Crit Rev Food Sci Nutr 2020;1–15.
- [3] Batiha O, Al-Deeb T, Al-zoubi E, Alsharu E. Impact of COVID-19 and other viruses on reproductive health. Andrologia 2020;52:e13791.

- [4] Day M. Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village. BMJ 2020;368:m1165.
- [5] Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med 2020;26:450–2.
- [6] Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun 2020;11:1–6.
- [7] Wang T, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet 2020;395:e52.
- [8] Yang J, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020.
- [9] Chaubey G. Coronavirus (SARS-CoV-2) and mortality rate in India: the winning edge. Front Public Health 2020;8:397.
- [10] AL-Khikani FHO. The role of blood group in COVID-19 infection: more information is needed. J. Nat. Sci. Med. 2020;3:225.
- [11] Dai X. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases. Eur J Prev Cardiol 2020;27:1436–7.
- [12] Esref A, et al. Association between the Rh blood group and the Covid-19 susceptibility. Int J Hematol Oncol 2020;30:081–6.
- [13] Göker H, et al. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. Turk J Med Sci 2020;50:679–83.
- [14] Padhi S, et al. ABO blood group system is associated with COVID-19 mortality: an epidemiological investigation in the Indian population. Transfus Clin Biol 2020;27: 253–8.
- [15] Almadhi MA, et al. The effect of ABO blood group and antibody class on the risk of COVID-19 infection and severity of clinical outcomes. Sci Rep 2021;11:1–5.
- [16] Muñiz-Diaz E, et al. Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. Blood Transfus 2021;19:54.
- [17] Glass RI, et al. Predisposition for cholera of individuals with O blood group possible evolutionary significance. Am J Epidemiol 1985;121:791–6.
- [18] Lin C-W, Chang Y-S, Wu S-C, CHENG K-S. Helicobacter pylori in gastric biopsies of Taiwanese patients with gastroduodenal diseases. Jpn J Med Sci Biol 1998;51: 13–23.
- [19] Hashan MR, et al. Association of dengue disease severity and blood group: a systematic review and meta-analysis. Rev Med Virol 2021;31:1–9.
- [20] Kalayanarooj S, et al. Blood group AB is associated with increased risk for severe dengue disease in secondary infections. J Infect Dis 2007;195:1014–7.
- [21] Fan Q, et al. Association between ABO blood group system and COVID-19 susceptibility in Wuhan. Front Cell Infect Microbiol 2020;10.
- [22] Ellinghaus D, et al. The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis. MedRxiv 2020.
- [23] Ellinghaus D, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med 2020.
- [24] Cordero AIH, et al. Multi-omics highlights ABO plasma protein as a causal risk factor for COVID-19. Hum Genet 2021:1–11.
- [25] Yamamoto F, Yamamoto M, Muñiz-Diaz E. Blood group ABO polymorphism inhibits SARS-CoV-2 infection and affects COVID-19 progression. Vox Sang 2020.
- [26] Kamatani Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 2010;42:210.
- [27] Astle WJ, et al. The allelic landscape of human blood cell trait variation and links to common complex disease. Cell 2016;167:1415–29.
- [28] Germain M, et al. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. Am J Hum Genet 2015;96:532–42.
- [29] Xue A, et al. Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. Nat Commun 2018;9:1–14.
- [30] Malik R, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 2018;50: 524–37.
- [31] Nikpay M, et al. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 2015;47:1121.
- [32] Schunkert H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011;43:333–8.
- [33] CARDIOGRAMplusC4D Consortium, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013;45:25–33.
- [34] Singh PP, et al. Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations. medRxiv 2021.
- [35] Singh PP, Chaubey G, et al. RE: why there is a second wave in India? e-letter. Science 2021.
- [36] Agarwal N, Thapliyal RM, Chatterjee K. Blood group phenotype frequencies in blood donors from a tertiary care hospital in north India. Blood Res 2013;48:51.
- [37] Kumar P, Rai V. Prevalence of blood groups in eastern UP population. 2020.[38] Kumar P, Rai V. Prevalence of of ABO and Rhesus (Rh) blood groups in eastern UP
- population. bioRxiv 2020. [39] Kumar P, Singh VK, Rai V. Study of ABO and Rh (D) blood groups in Kshatriya
- (Rajput) of Jaunpur District, Uttar Pradesh. Anthropology 2009;11:303–4.[40] Kumar P, Maurya S, Rai V. Distribution of ABO and Rh (D) blood groups among
- Koari (backward Caste) population of Jaunpur district. Anthropology 2009;11: 309–10.
- [41] Kumar P, Saima S, Rai V. Study of ABO and Rh (D) blood groups in Sunni Muslims of Jaunpur District, Uttar Pradesh, India. Anthropology 2010;12:225–6.
- [42] Rai V, Kumar P. Genetic analysis of ABO and Rh blood groups in backward caste population of Uttar Pradesh, India. Not. Sci. Biol. 2011;3:07–14.

P.P. Singh et al.

- [43] Rai V, Kumar P. The incidence of ABO blood group in Muslim population of Uttar Pradesh, India. J Appl Biosci 2010;36:191–5.
 [44] Murhekar MV, et al. SARS-CoV-2 antibody seroprevalence in India, August–september, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health 2021;9:e257–66.
- [45] Murhekar MV, et al. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. Indian J Med Res 2020;152:48.